{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0010","upperLimit":"0.2035","value":"0.0400"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0.1482","value":"0"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0.1951","value":"0"},{"groupId":"OG003","lowerLimit":"0.0527","upperLimit":"0.8534","value":"0.4000"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"0.2471","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"13"}],"units":"Participants"}],"description":"Will be defined as complete response or incomplete blood count recovery. Estimated by the number of patients who achieve an incomplete blood count recovery or complete response divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true complete response rate will be calculated in each arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients on Arm A or Arm C experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.","id":"OG000","title":"Arm A (CLL)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG001","title":"Arm B (NHL)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients on Arm A or Arm C experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.","id":"OG002","title":"Arm C (CLL With Richters)"},{"description":"CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG003","title":"Arm A (Continuation Phase)"},{"description":"CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator.","id":"OG004","title":"Arm C (Continuation Phase)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Complete Response Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}